According to HealthDay News, ?In March, the FDA requested that all manufacturers of sedative-hypnotic drug products -- a class of drugs used to induce and/or maintain sleep -- strengthen their product labeling to include stronger warnings about potential risks. Those risks include severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving. Sleep driving is defined as driving while not fully awake after taking a sedative-hypnotic drug, with no memory of the event.?

The FDA has stated that thirteen manufacturers have received authorization from the FDA to produce zolpidem tartrate tablets. Those manufacturers are, Mylan Pharmaceuticals Inc.; TEVA Pharmaceuticals USA; Roxane Laboratories Inc.; Watson Laboratories Inc.; Ranbaxy Laboratories Ltd.; Dr. Reddys Laboratories Ltd.; Apotex Inc.; Synthon Pharmaceuticals Inc.; Genpharm Inc.; Mutual Pharmaceutical Company Inc.; Caraco Pharmaceutical Laboratories Ltd.; Carlsbad Technology Inc.; and Lek Pharmaceuticals.

Drugs in this class including Ambien recently were required by the FDA to include a stronger warning of side affects including severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving. As oddly as it sounds sleep driving has been a major issue surrounding Ambien, and is driving while not fully awake, with no memory of the event.

For more related articles or to subscribe to our feed please visit this Consumer Advocacy website for more information on ordering from an online <---****HYPERLINK****--->"http://www.noprescriptioneeded.com">no prescription pharmacy.